Inspired by science
Leveraging deep expertise in chemistry and biology, as well as strategic partnerships, we are advancing various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, antibody-drug conjugates and other innovative treatments.
Our discovery teams are advancing multiple small molecule programs internally and through our industry collaborations.
Our R&D programs include next-generation approaches to established targets, as well as opportunities to be first-in-class by applying a range of modalities and mechanisms of action across biologics and small molecules.